Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prucalopride
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Prucalopride is a selective, high-affinity serotonin 5-HT4 receptor agonist used primarily for the treatment of chronic idiopathic constipation (CIC) in adults. By stimulating 5-HT4 receptors located throughout the gastrointestinal tract—especially in smooth muscle cells, enterochromaffin cells, and the myenteric plexus—prucalopride enhances peristalsis and increases colonic motility. This action accelerates colonic transit time and promotes more frequent spontaneous complete bowel movements. Prucalopride’s selectivity for 5-HT4 over other serotonin receptors reduces cardiovascular risks associated with earlier drugs in this class. It also accelerates gastric emptying and small bowel transit. The drug was developed to address impaired motility associated with chronic constipation that is not caused by other diseases or medications[1][2][3][4][6][8].
- Brand names
- MotegrityResolor
- Other names
- prucaloprideTA211TA-211TA 211
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)HTR4 (5-Hydroxytryptamine receptor 4)DRD4 (Dopamine D4 Receptor)SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on prucalopride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prucalopride.